Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | IL6 | P05231 | 4/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918196 | 0.82 | IL6 (0.43) | GAAALDH1A1IL6MAPT | |
| SCHEMBL12411970 | 0.81 | ALDH1A1 (0.43) | GAAALDH1A1IL6TSHR | |
| SCHEMBL1919243 | 0.81 | IL6 (0.42) | GAAALDH1A1IL6GFERFPR2 | |
| SCHEMBL1918531 | 0.81 | IL6 (0.38) | GAAALDH1A1IL6GFERFPR2 | |
| SCHEMBL1919059 | 0.79 | IL6 (0.49) | ALDH1A1IL6MAPTTSHR | |
| SCHEMBL4582204 | 0.76 | IL6 (0.52) | GAAALDH1A1IL6MAPTTSHR | |
| SCHEMBL4134498 | 0.76 | IL6 (0.61) | IL6 | |
| SCHEMBL4136054 | 0.70 | IL6 (0.36) | ALDH1A1IL6MAPTFPR2 | |
| SCHEMBL1917399 | 0.69 | IL6 (0.68) | ALDH1A1IL6 | |
| SCHEMBL17160621 | 0.67 | KMT2A (0.55) | ALDH1A1MAPTFPR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664221-B2 | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20110166151-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045842-A1 | METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT | UACA, PKLR, CYSLTR1 | GAA 2363/4885ALDH1A1 1587/4885IL6 23/4885 |
| US-20110166151-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT | NR3C1, GRK4, MC2R | GAA 4213/4885ALDH1A1 3674/4885IL6 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.